116 First-in-human clinical trial with SPL84, an antisense oligonucleotide for treatment of people with cystic fibrosis with the 3849 +10 Kb C - > T mutation
| Autor: | Caraco, Y., Wanounou, M., Friedman, L., Cohen, A., Hart, G., Kerem, E. |
|---|---|
| Zdroj: | In Journal of Cystic Fibrosis October 2023 22 Supplement 3:S61-S61 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect